This new article publication from Acta Pharmaceutica Sinica B, discusses a bispecific killer engager for targeted depletion ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.